A recent study reports a new biomarker panel, comprised of 28 physical and molecule measures, that could successfully confirm the diagnosis of warzone-related post-traumatic stress disorder (PTSD) with 77% accuracy.
In a new study, researchers from Osaka University (Japan) have demonstrated that measuring methylation of microRNA could accurately distinguish individuals with early pancreatic cancer from healthy controls.
Researchers have discovered unique populations of neurons in the spinal cords of patients who died of amyotrophic lateral sclerosis that could be utilized as potential drug targets.
A multiplex HRMS assay for quantifying selected human plasma bile acids as candidate OATP biomarkers
This preliminary communication from Bioanalysis discusses the application of selected bile acids in plasma as endogenous probes for assessing drug–drug interactions involving hepatic drug transporters such as the organic anion-transporting polypeptides.
In this interview, Hanna Ritzén (Mercodia; Uppsala, Sweden) provides an insight into her recent article on classification of commercial LBA kits for biomarkers, and why this area of bioanalysis is important.
In this interview, Stephanie Traub (Cancer Research UK; London, UK) discusses her work as a biomarker specialist and the challenges she faces when developing biomarker strategies.
In this editorial Sally Fischer (Genentech; CA, USA) explores ligand binding assay technologies: how to match the right tool to the bioanalytical challenge.
Recommendations for classification of commercial LBA kits for biomarkers in drug development from the GCC for bioanalysis
In this White Paper from Bioanalysis the authors highlight the need the bioanalytical community has for commercial kits able to be used for regulated drug development.
In this interview, Rafiq Islam (Celerion) discusses the impact FDA guidance for industry on bioanalytical method validation has had on biomarker research in recent years and shares his thoughts on technologies that will change biomarker research in the future.
2018 White Paper on Recent Issues in Bioanalysis: focus on immunogenicity assays by hybrid LBA/LCMS and regulatory feedback (Part 2 – PK, PD & ADA assays by hybrid LBA/LCMS & regulatory agencies’ inputs on bioanalysis, biomarkers and immunogenicity)
This part of the 2018 White Paper published in Bioanalysis focuses on the recommendations for PK, PD and ADA assays by hybrid LBA/LCMS and regulatory agencies’ input.